Baseline characteristics
| Characteristics | No transfusion (n=289) | Transfusion (n=323) | P value* |
| Treatment arm | |||
| PDS, n (%) | 126 (44%) | 174 (54%) | 0.01 |
| NACT, n (%) | 163 (56%) | 149 (46%) | |
| Age (years) | 0.22 | ||
| Mean±SD | 63±10 | 62±10 | |
| Median (range) | 63 (34–84) | 62 (25–87) | |
| BMI, kg/m2† | 0.46 | ||
| Mean±SD | 26±5 | 26±5 | |
| Median (range) | 25 (16–48) | 25 (17–42) | |
| WHO performance status, n (%)‡ | 0.04 | ||
| 0 | 116 (40%) | 161 (50%) | |
| 1 | 134 (47%) | 129 (40%) | |
| 2 | 39 (14%) | 32 (10%) | |
| Histologic type, n (%) § | |||
| Serous | 164 (57%) | 218 (68%) | 0.01 |
| Mucinous | 10 (4%) | 8 (3%) | |
| Clear-cell | 2 (1%) | 7 (2%) | |
| Endometrioid | 6 (2%) | 10 (3%) | |
| Undifferentiated | 52 (18%) | 37 (12%) | |
| Mixed | 0 (0%) | 3 (1%) | |
| Unclassifiable | 28 (10%) | 25 (8%) | |
| Other/unknown unclassifiable | 27 (9%) | 14 (1%) | |
| Histologic grade, n (%)¶ | |||
| Well-differentiated | 10 (4%) | 12 (4%) | 0.22 |
| Moderately differentiated | 36 (13%) | 57 (18%) | |
| Poorly differentiated | 120 (42%) | 133 (41%) | |
| Unknown | 123 (43%) | 119 (37%) | |
| Stage, n (%)** | |||
| IIIC | 211 (73%) | 256 (80%) | 0.07 |
| IV | 78 (27%) | 66 (20%) | |
| Primary tumor, n (%)†† | |||
| Epithelial ovarian | 244 (85%) | 284 (90%) | 0.66 |
| Peritoneal | 23 (8%) | 18 (6%) | |
| Fallopian tube | 1 (0.3%) | 2 (1%) | |
| Adenocarcinoma | 20 (7%) | 17 (5%) | |
| Pre-operative platelets (%) | 0.89 | ||
| ≤150 | 3 (1%) | 3 (1%) | |
| ≥ 150 | 286 (9%) | 320 (9%) |
*χ2 and Fisher’s exact tests were used for categorical variables, and Mann-Whitney test to compare medians between cohorts for continuous variables.
†Missing data for 12 no transfusion patients.
‡Missing data for two no transfusion patients and one transfusion patient
§Missing data for one transfusion patient.
¶Missing data for two transfusion patients.
**Missing data for one transfusion patient.
††Missing data for one no transfusion patient and two transfusion patients.
BMI, body mass index; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery.